Animal Models of Breast Cancer Bone Metastasis

  • Claudia Tulotta
  • Arwin Groenewoud
  • B. Ewa Snaar-Jagalska
  • Penelope OttewellEmail author
Part of the Methods in Molecular Biology book series (MIMB, volume 1914)


This chapter is designed to provide a comprehensive overview outlining the different in vivo models available for research into breast cancer bone metastasis. The main focus is to guide the researcher through the methodological processes required to establish and utilize these models within their own laboratory. These detailed methods are designed to enable the acquisition of accurate and meaningful results that can be used for publication and future translation into clinical benefit for women with breast cancer-induced bone metastasis.

Key words

Breast cancer Bone metastasis Mouse Zebrafish 


  1. 1.
    Coleman RE (1997) Skeletal complications of malignancy. Cancer 80:1588–1594CrossRefGoogle Scholar
  2. 2.
    Ottewell PD, O’Donnell L, Holen I (2015) Molecular alterations that drive breast cancer metastasis to bone. Bonekey Rep 4:643CrossRefGoogle Scholar
  3. 3.
    Cox TR, Rumney RMH, Schoof EM, Perryman L, Høye AM, Agrawal A, Bird D, Latif NA, Forrest H, Evans HR, Huggins ID, Lang G, Linding R, Gartland A, Erler JT (2015) The hypoxic cancer secretome induces pre-metastatic bone lesions through lysyl oxidase. Nature 522(7554):106–110CrossRefGoogle Scholar
  4. 4.
    Wright LE, Ottewell PD, Rucci N, Peyruchaud O, Pagnotti GM, Chiechi A, Buijs JT, Sterling JA (2016) Murine models of breast cancer bone metastasis. Bonekey Rep 5:804CrossRefGoogle Scholar
  5. 5.
    Holen I, Walker M, Nutter F, Fowles A, Evans CA, Eaton CL, Ottewell PD (2016) Oestrogen receptor positive breast cancer metastasis to bone: inhibition by targeting the bone microenvironment in vivo. Clin Exp Metastasis 33(3):211–224CrossRefGoogle Scholar
  6. 6.
    Ottewell PD, Deux B, Mönkkönen H, Cross S, Coleman RE, Clezardin P, Holen I (2008) Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo. Clin Cancer Res 14(14):4658–4666CrossRefGoogle Scholar
  7. 7.
    Ottewell PD, Woodward JK, Lefley DV, Evans CA, Coleman RE, Holen I (2009) Anticancer mechanisms of doxorubicin and zoledronic acid in breast cancer tumor growth in bone. Mol Cancer Ther 8(10):2821–2832CrossRefGoogle Scholar
  8. 8.
    Withana NP, Blum G, Sameni M, Slaney C, Anbalagan A, Olive MB, Bidwell BN, Edgington L, Wang L, Moin K, Sloane BF, Anderson RL, Bogyo MS, Parker BS (2012) Cathepsin B inhibition limits bone metastasis in breast cancer. Cancer Res 72(5):1199–1209CrossRefGoogle Scholar
  9. 9.
    Bretschi M, Merz M, Komljenovic D, Berger MR, Semmler W, Bäuerle T (2011) Cilengitide inhibits metastatic bone colonization in a nude rat model. Oncol Rep 26(4):843–851PubMedGoogle Scholar
  10. 10.
    Tulotta C, He S, van der Ent W, Chen L, Groenewoud A, Spaink HP, Snaar-Jagalska BE (2016) Imaging cancer angiogenesis and metastasis in a zebrafish embryo model. Adv Exp Med Biol 916:239–263CrossRefGoogle Scholar
  11. 11.
    Mercatali L, La Manna F, Groenewoud A, Casadei R, Recine F, Miserocchi G, Pieri F, Liverani C, Bongiovanni A, Spadazzi C, de Vita A, van der Pluijm G, Giorgini A, Biagini R, Amadori D, Ibrahim T, Snaar-Jagalska E (2016) Development of a patient-derived xenograft (PDX) of breast cancer bone metastasis in a zebrafish model. Int J Mol Sci 17(8):E1375. Scholar
  12. 12.
    Lee JH, Kim B, Jin WJ, Kim JW, Kim HH, Ha H, Lee ZH (2014) Trolox inhibits osteolytic bone metastasis of breast cancer through both PGE2-dependent and independent mechanisms. Biochem Pharmacol 91(1):51–60CrossRefGoogle Scholar
  13. 13.
    Kuperwasser C, Dessain S, Bierbaum BE, Garnet D, Sperandio K, Gauvin GP, Naber SP, Weinberg RA, Rosenblatt M (2005) A mouse model of human breast cancer metastasis to human bone. Cancer Res 65(14):6130–6138CrossRefGoogle Scholar
  14. 14.
    Holen I, Nutter F, Wilkinson JM, Evans CA, Avgoustou P, Ottewell PD (2015) Human breast cancer bone metastasis in vitro and in vivo: a novel 3D model system for studies of tumour cell-bone cell interactions. Clin Exp Metastasis 32(7):689–702CrossRefGoogle Scholar
  15. 15.
    Ottewell PD, Wang N, Brown HK, Reeves KJ, Fowles CA, Croucher PI, Eaton CL (2014) Holen I. Zoledronic acid has differential antitumor activity in the pre- and postmenopausal bone microenvironment in vivo. Clin Cancer Res 20(11):2922–2932CrossRefGoogle Scholar
  16. 16.
    Suva LJ, Washam C, Nicholas RW, Griffin RJ (2011) Bone metastasis: mechanisms and therapeutic opportunities. Nat Rev Endocrinol 7(4):208–218CrossRefGoogle Scholar
  17. 17.
    Nutter F, Holen I, Brown HK, Cross SS, Evans CA, Walker M, Coleman RE, Westbrook JA, Selby PJ, Brown JE, Ottewell PD (2014) Different molecular profiles are associated with breast cancer cell homing compared with colonisation of bone: evidence using a novel bone-seeking cell line. Endocr Relat Cancer 21(2):327–341CrossRefGoogle Scholar
  18. 18.
    Wetterwald A, van der Pluijm G, Que I, Sijmons B, Buijs J, Karperien M, Löwik CWGM, Gautschi E, Thalmann GN, Cecchini MG (2002) Optical imaging of cancer metastasis to bone marrow. Am J Pathol 160(3):1143–1153CrossRefGoogle Scholar
  19. 19.
    Pécheur I, Peyruchaud O, Serre CM, Guglielmi J, Voland C, Bourre F, Margue C, Cohen-Solal M, Buffet A, Kieffer N, Integrin CP (2002) alpha(v)beta3 expression confers on tumor cells a greater propensity to metastasize to bone. FASEB J 16(10):1266–1268CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Claudia Tulotta
    • 1
  • Arwin Groenewoud
    • 2
  • B. Ewa Snaar-Jagalska
    • 2
  • Penelope Ottewell
    • 1
    Email author
  1. 1.Department of Oncology and Metabolism, Mellanby Centre for Bone ResearchUniversity of SheffieldSheffieldUK
  2. 2.Institute of BiologyLeiden UniversityLeidenThe Netherlands

Personalised recommendations